Methods of modulating drug plasma levels using erythrohydroxybupropion
First Claim
Patent Images
1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering erythrohydroxybupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein erythrohydroxybupropion and dextromethorphan are the sole active agents administered to the human being, wherein the erythrohydroxybupropion is administered in an amount that results in an AUC0-12 of dextromethorphan that is at least about 40 ng·
- hr/mL, and wherein, on the eighth day that erythrohydroxybupropion and dextromethorphan are co-administered, the AUC0-12 of dextromethorphan is at least about 20 times the AUC0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without erythrohydroxybupropion.
4 Assignments
0 Petitions
Accused Products
Abstract
This disclosure relates to methods administering erythrohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed
180 Citations
18 Claims
-
1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering erythrohydroxybupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein erythrohydroxybupropion and dextromethorphan are the sole active agents administered to the human being, wherein the erythrohydroxybupropion is administered in an amount that results in an AUC0-12 of dextromethorphan that is at least about 40 ng·
- hr/mL, and wherein, on the eighth day that erythrohydroxybupropion and dextromethorphan are co-administered, the AUC0-12 of dextromethorphan is at least about 20 times the AUC0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without erythrohydroxybupropion.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- 11. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering erythrohydroxybupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein erythrohydroxybupropion and dextromethorphan are the sole active agents administered to the human being, wherein the erythrohydroxybupropion is administered in an amount that results in a Cmax of dextromethorphan that is at least about 6 ng/mL, and wherein, on the eighth day that erythrohydroxybupropion and dextromethorphan are co-administered, the AUC0-12 of dextromethorphan is at least about 20 times the AUC0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without erythrohydroxybupropion.
- 15. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering erythrohydroxybupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein erythrohydroxybupropion and dextromethorphan are the sole active agents administered to the human being, wherein the erythrohydroxybupropion is administered in an amount that results in a Cavg of dextromethorphan, over the period between two separate and consecutive administrations of dextromethorphan, that is at least about 5 ng/mL, and wherein, on the eighth day that erythrohydroxybupropion and dextromethorphan are co-administered, the AUC0-12 of dextromethorphan is at least about 20 times the AUC0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without erythrohydroxybupropion.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeAntecip Bioventures II LLC
-
Original AssigneeAntecip Bioventures II LLC
-
InventorsTabuteau, Herriot
-
Primary Examiner(s)BARSKY, JARED
-
Application NumberUS14/628,062Publication NumberTime in Patent Office529 DaysField of SearchNoneUS Class Current1/1CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/137 Arylalkylamines, e.g. amphe...A61K 31/138 Aryloxyalkylamines, e.g. pr...A61K 31/4748 forming part of bridged rin...A61K 31/485 Morphinan derivatives, e.g....A61K 9/0053 Mouth and digestive tract, ...
